Recognized for the 13th consecutive year, the global CX leader continues to set the standard for CXM excellence Foundever®, the next-generation service leader reinventing customer experience (CX), has ...

Daiichi Sankyo and Merck & Co.’s phase 3 program for their investigational antibody-drug conjugate has been hit with a hold after an unexpected number of deaths were reported in the global trial. “Due ...

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapy ALPACCA pivotal trial is designed to ...

Emerging markets are entering 2026 as a central force in the reordering of global growth. All in all, we believe a stable U.S. dollar, ample global liquidity, and strong demand for industrial ...

Australian actor Martin Grelis, who appeared in the 1999 first installment of The Matrix film series, has died at the age of 57. “Martin was a bright spark who lit up every room he was in—a talented ...

In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for AstraZeneca-partnered Enhertu in first-line HER2-positive breast cancer but paused a phase 3 ...

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody therapy designed to treat Alzheimer's disease. The French pharma is paying ...

As the Central Economic Work Conference was held last week, observers are closely watching the direction and priorities of China's economy for the coming year. Looking back at the economic performance ...

About the authors: Marcello Estevão is managing director and chief economist at the Institute of International Finance and a professor at Georgetown University. Jonathan Fortun is a senior economist ...

Nothing kills the buzz of a big win faster than a “Verification Required” email. You shouldn’t have to send a selfie just to ...